# Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria

> **NCT06238544** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Chengdu Suncadia Medicine Co., Ltd.** · enrollment: 132 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

- **DRUG:** HRS-5965 tablets
- **DRUG:** HRS-5965 Capsules

## Key facts

- **NCT ID:** NCT06238544
- **Lead sponsor:** Chengdu Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-06
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06238544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06238544, "Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06238544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*